Citius Intangible Assets from 2010 to 2024
| CTOR Stock | 0.85 0.13 13.27% |
Intangible Assets | First Reported 2010-12-31 | Previous Quarter 36 M | Current Value 32 M | Quarterly Volatility 2.2 M |
Check Citius Oncology, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Citius Oncology,'s main balance sheet or income statement drivers, such as Tax Provision of 460.8 K, Selling General Administrative of 5.1 M or Total Revenue of 0.0, as well as many indicators such as . Citius financial statements analysis is a perfect complement when working with Citius Oncology, Valuation or Volatility modules.
Citius |
Pair Trading with Citius Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology, will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
Moving against Citius Stock
| 0.81 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.8 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.69 | FLGC | Flora Growth Corp | PairCorr |
| 0.67 | VRDN | Viridian Therapeutics | PairCorr |
| 0.55 | EXEL | Exelixis | PairCorr |
The ability to find closely correlated positions to Citius Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Oncology, to buy it.
The correlation of Citius Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Oncology, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.